Moxee

ThinkCyte just raised $32 million in Series C funding. Here's what they’re fixing: 👇 𝗙𝗮𝘀𝘁𝗲𝗿 𝗱𝗿𝘂𝗴 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴: VisionSort speeds up and streamlines the process. 𝗟𝗮𝗯𝗲𝗹-𝗳𝗿𝗲𝗲 𝗰𝗲𝗹𝗹 𝗮𝗻𝗮𝗹𝘆𝘀𝗶𝘀: Ghost Cytometry lets researchers analyze cells without external labels, keeping the data pure. 𝗖𝗼𝗺𝗽𝗹𝗲𝘅 𝗽𝗵𝗲𝗻𝗼𝘁𝘆𝗽𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗰𝗮𝘁𝗶𝗼𝗻: Their tech reveals detailed single-cell phenotypes, giving researchers a deeper look. 𝗘𝘅𝗽𝗮𝗻𝗱𝗲𝗱 𝗱𝗿𝘂𝗴 𝘀𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴: VisionSort enhances biopharma workflows and expands screening options. The funds will fuel the global growth of VisionSort. Nice work, ThinkCyte! 👏 #lifesciences #funding

#StartupSpotlight - Biomatter Biomatter is a SynBio company that creates new proteins and enzymes using their Intelligent Architecture platform. They want to change health and sustainable manufacturing by making proteins with unique functions and properties. 📖 Biomatter.ai started in 2018 in Vilnius, Lithuania. 📖 They were created to solve the problems with old methods of protein engineering, which are slow, expensive, and not very accurate. 📖 By using AI and computer tools, Biomatter.ai speeds up the process and opens new possibilities for engineered proteins in healthcare and manufacturing. 𝗣𝗿𝗼𝗯𝗹𝗲𝗺 𝗦𝗼𝗹𝘃𝗲𝗱: Efficiency: Old methods are slow and use a lot of resources. Precision: Their platform makes designing proteins more accurate, allowing for specific and new functions hard to achieve with traditional methods. Scalability: The platform can handle huge amounts of protein data, making it useful for large-scale projects in healthcare, sustainability, and industry. 𝗠𝗶𝗹𝗲𝘀𝘁𝗼𝗻𝗲𝘀: 2019: Published a study showing their AI tool can analyze large enzyme datasets and design new enzymes. 2021: Raised €500,000 in seed funding to improve their AI-driven protein design technology. 2023: Partnered with ArcticZymes Technologies ASA to create new enzyme-based products using their platform. 2024: Secured €6.5 million in funding to expand their protein design capabilities. Achievements in 2024 Check 'em out! 👏

The first CRISPR medicine was approved yesterday. 😲 ... And, it's in the UK!! The decision could transform the treatment of sickle-cell disease. This is the first medicine based on CRISPR technology that has been approved... ANYWHERE!! (Perhaps the only benefit of Brexit 🤣) Link in the comments!

Last week was HUGE for funding! 💸 👏 Here's the biotech round-up: [1] Genezen - Cell Therapy, Indiana - $18,500,000 (Venture Round) [2] Stellaromics Inc. - Multi-Omics, Massachusetts - $25,000,000 (Series A) [3] Progenx - Neuroscience, New York - $15,000,000 (Series A) [4] GENOME INSIGHT INC. - Multi-Omics, New York - $23,000,000 (Series A) [5] Gate Bioscience - Protein Degradation, California - $60,000,000 (Series A) [6] Siren Biotechnology - AAV immuno-gene therapy, California - $4,000,000 (Grant) [7] Lucid Diagnostics - Cancer Dx, New York - $5,000,000 (Venture Round) [8] Aqtual, Inc. - Precision Medicine, California - $16,000,000 (Series A) [9] Engine Biosciences - Biomarker Discovery, California - $27,000,000 (Series A) [10] Annovis Bio, Inc. - Alzheimer’s and Parkinson’s, Pennsylvania - $7,500,000 (Post) [11] Annovis Bio, Inc. - Alzheimer’s and Parkinson’s, Pennsylvania - $7,500,000 (Post) [12] 100X Bioassay - T-Cell Research, Massachusetts - $40,000 (Pre-seed) [13] BRAINBox Solutions, Inc. - mTBI, Diagnosis & Prognosis, Virginia - (Series B) [14] Granata Bio - Fertility Solutions , Massachusetts - $96,667 (Seed Round) [15] MapLight Therapeutics, Inc. - Therapeutics for CNS disorders, California - $225,000,000, (Series C) #biotech #funding